Premium
Physician Barriers to Incorporating Pharmacogenetic Treatment Strategies for Nicotine Dependence Into Clinical Practice
Author(s) -
Schnoll RA,
Shields AE
Publication year - 2011
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2010.267
Subject(s) - pharmacogenetics , clinical pharmacology , medicine , preparedness , clinical practice , intensive care medicine , personalized medicine , nicotine dependence , pharmacology , nicotine , bioinformatics , family medicine , psychiatry , biology , political science , biochemistry , gene , genotype , law
Advances in genomics research may improve health outcomes by tailoring treatment according to patients’ genetic profiles. The treatment of nicotine dependence, in particular, may soon encompass pharmacogenetic treatment models. Realizing the benefits of such treatment strategies may depend on physicians’ preparedness to incorporate genetic testing into clinical practice. This article describes barriers to clinical integration of pharmacogenetic treatments that will need to be addressed to realize the benefits of individualized smoking‐cessation treatment. Clinical Pharmacology & Therapeutics (2011) 89 3, 345–347. doi: 10.1038/clpt.2010.267